Compare NIO Inc. (NIO) vs Oscar Health Inc (OSCR) Price & Performance

NIO trades at $3.79, down 0.26% today, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 revenue growth of 69.1% year-over-year to $4.74 billion (Seeking Alpha, 2026-09-03), but missed revenue expectations. Vehicle margins improved to 18.4%, and cash flow turned positive, yet net losses persist. Analyst consensus is mixed, with a $5.50 price target suggesting 45% upside from current levels.

Outlook: NIO shows operational progress with narrowing losses and brand diversification, but high debt and Chinese EV competition pose risks. The stock's low P/S ratio of 0.54 indicates potential undervaluation if profitability improves. Investors face volatility from macroeconomic headwinds and execution challenges in achieving sustained positive earnings.

Oscar Health (OSCR) trades at $33.01, up 2.36% today and approaching its 52-week high of $33.10. The stock shows strong technical momentum with bullish moving averages and has surged 109% year-to-date. Fundamentally, revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Recent earnings beats and membership growth to 2.96 million support the bullish case, though valuation metrics like P/E of 25.39 and P/B of 4.97 suggest premium pricing.

Outlook remains positive with strong revenue growth and profitability improvements, but risks include high valuation multiples and dependence on sustained membership growth. Analyst consensus is mixed with 27% buy ratings and a $30.67 price target below current levels, indicating caution despite technical strength. Key catalysts include continued operational efficiency gains and AI integration, while medical cost management remains critical.